Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Eric Jonasch, MD, on How NCCN Clinical Practice Guidelines in Oncology® Updates May Affect Treatment Selection in Metastatic Kidney Cancer

Posted: Monday, September 30, 2019

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses new combination therapies, which may displace single-agent tyrosine kinase inhibitors in the front-line setting, and the challenges faced in sequencing subsequent therapies.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.